See the DrugPatentWatch profile for Brodalumab
When does brodalumab’s patent (and related exclusivity) expire?
The provided information does not include the specific patent(s), jurisdiction(s), or the relevant regulatory exclusivity terms for brodalumab (brand name: Siliq). Patent expiry dates depend on where the drug is marketed (e.g., US vs. EU vs. UK) and on which protection layers apply (compound patents, method-of-use patents, formulation patents, and regulatory exclusivities such as biologic exclusivity).
If you share the country/region you care about (for example, US or EU) and whether you mean “patent expiry” specifically or “market exclusivity,” I can narrow to the correct date(s).
Does brodalumab have multiple patents with different expiry dates?
Yes. For biologics, companies usually hold more than one patent covering different aspects of the product (active molecule, manufacturing/process, and specific indications). That means exclusivity can end for one patent while other patents still restrict generic or biosimilar entry, depending on the legal challenges and the scope of each patent.
Can biosimilars launch before all patents expire?
In many jurisdictions, a biosimilar may launch once it clears the relevant regulatory pathway and any court rulings or patent “stay” mechanisms tied to the challenged patents. Even if some patents have not expired, a biosimilar can sometimes proceed if it is not covered by enforceable patents (or after a legal decision that narrows coverage).
What do people usually mean by “patent expiry” for brodalumab?
Searchers often conflate three different timing concepts:
- The expiry of the primary drug substance patent (often the longest-lived).
- Expiry of secondary patents (methods, formulations, or indications).
- Regulatory exclusivity or data protection periods (which can delay marketing even if some patents lapse).
To give an accurate date, the needed detail is which of these you mean, and for which jurisdiction.
What information would let you pinpoint the exact expiry date?
If you tell me:
1) region (US, EU, UK, Canada, etc.), and
2) whether you want patent expiry or biosimilar/market exclusivity, and
3) (optional) the brand/indication scope you care about (psoriasis vs. other),
I can map the likely protection layers and provide the most relevant expiry timeline.
Sources
No sources were provided in the prompt, so no citations can be listed.